Concepedia

Publication | Open Access

Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer: final survival analysis of the ADEBAR study

DOIFull Paper Access

12

Citations

18

References

2016

Year

Wolfgang Janni, Nadia Harbeck, Brigitte Rack, Doris Augustin, J Jueckstock, A. Wischnik, K Annecke, Christoph Scholz, Jens Huober, T. Zwingers,
British Journal of Cancer

Abstract

EC-Doc provides a feasible and effective alternative therapy option to FEC120 with a different safety profile in this high-risk breast cancer cohort.

References

YearCitations

Page 1